{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:10:55Z","timestamp":1791094255524,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T00:00:00Z","timestamp":1126569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00280-005-0023-6","type":"journal-article","created":{"date-parts":[[2005,9,12]],"date-time":"2005-09-12T11:19:59Z","timestamp":1126523999000},"page":"199-206","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study"],"prefix":"10.1007","volume":"57","author":[{"given":"Cheri E.","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kastrissios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonius A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Grinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,9,13]]},"reference":[{"key":"23_CR1","volume-title":"Textbook of malignant haematology","author":"P Fenaux","year":"1999","unstructured":"Fenaux P (1999) Myelodysplastic syndromes. In: Degos L, Linch DC, Lowenberg B (eds) Textbook of malignant haematology. Martin Dunitz, London"},{"key":"23_CR2","first-page":"374","volume-title":"Current therapy in cancer","author":"CP Burns","year":"1999","unstructured":"Burns CP (1999) Myelodysplastic syndromes. In: Foley JF, Vose JM, Armitage JO (eds) Current therapy in cancer. Saunders, Philadelphia, pp 374\u2013381"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","volume":"17","author":"M Beran","year":"1999","unstructured":"Beran M, Estey E, OBrien S, Cortes J, Koller CA, Giles FJ et al (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17:2819\u20132830","journal-title":"J Clin Oncol"},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","volume":"88","author":"M Beran","year":"1996","unstructured":"Beran M, Kantarjian H, OBrien S, Koller C, Al-Bitar M, Arbuck S et al (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473\u20132479","journal-title":"Blood"},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","volume":"92","author":"M Beran","year":"2001","unstructured":"Beran M, Shen Y, Kantarjian H, O\u2019Brien S, Koller CA, Giles FJ et al (2001) High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate adjusted comparison of five regimens. Cancer 92:1999\u20132015","journal-title":"Cancer"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.1998.16.7.2557","volume":"16","author":"MD DeMario","year":"1998","unstructured":"DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557\u20132567","journal-title":"J Clin Oncol"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.1998.16.10.3302","volume":"16","author":"RC Lilenbaum","year":"1998","unstructured":"Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL et al (1998) Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a cancer and leukemia Group B study. J Clin Oncol 16:3302\u20133309","journal-title":"J Clin Oncol"},{"key":"23_CR8","first-page":"1153","volume":"4","author":"CJ Gerrits","year":"1998","unstructured":"Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME et al (1998) Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 4:1153\u20131158","journal-title":"Clin Cancer Res"},{"key":"23_CR9","volume-title":"Patient compliance in medical practice and clinical trials","author":"J Cramer","year":"1991","unstructured":"Cramer J, Spilker B (1991) Patient compliance in medical practice and clinical trials. Raven Press, New York"},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.pharmtox.37.1.451","volume":"37","author":"H Kastrissios","year":"1997","unstructured":"Kastrissios H, Blaschke TF (1997) Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol 37:451\u2013475","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"23_CR11","volume-title":"NONMEM Users Guide, NONMEM Project Group","author":"SL Beal","year":"1992","unstructured":"Beal SL, Sheiner LB (1992) NONMEM Users Guide, NONMEM Project Group. UCSF, San Francisco"},{"key":"23_CR12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic\u2013pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511\u2013528","journal-title":"J Pharmacokinet Biopharm"},{"key":"23_CR13","unstructured":"National Cancer Institute (1998) Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1992.10.6.1007","volume":"10","author":"C Lee","year":"1992","unstructured":"Lee C, Nicholson P, Souhami R, Deshmukh A (1992) Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 10:1007\u20131013","journal-title":"J Clin Oncol"},{"key":"23_CR15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1200\/JCO.1993.11.6.1189","volume":"11","author":"D Waterhouse","year":"1993","unstructured":"Waterhouse D, Calzone K, Mele C, Brenner D (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11:1189\u20131197","journal-title":"J Clin Oncol"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3810\/pgm.1997.09.323","volume":"102","author":"K Ennis","year":"1997","unstructured":"Ennis K, Reichard R (1997) Maximizing drug compliance in the elderly. Postgrad Med 102:211\u2013224","journal-title":"Postgrad Med"},{"key":"23_CR17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.bjc.6690532","volume":"80","author":"V Herben","year":"1999","unstructured":"Herben V, Rosing H, tenBokkel Huinink W, van Zomeren D, Batchelor D, Doyle E et al (1999) Oral topotecan: bioavailability and the effect of food co-administration. Br J Cancer 80:1380\u20131386","journal-title":"Br J Cancer"},{"key":"23_CR18","first-page":"2685","volume":"6","author":"WJ Loos","year":"2000","unstructured":"Loos WJ, Gelderblom HJ, Sparreboom A, Verweij J, de Jonge MJ (2000) Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 6:2685\u20132689","journal-title":"Clin Cancer Res"},{"key":"23_CR19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.1997.15.3.1087","volume":"15","author":"G Creemers","year":"1997","unstructured":"Creemers G, Gerrits C, Eckhardt J, Schellens J, Burris H, Planting A et al (1997) Phase I and pharmacologic study of oral topotecan administered twice daily for 21\u00a0days to adult patients with solid tumors. J Clin Oncol 15:1087\u20131093","journal-title":"J Clin Oncol"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0959-8049(97)10173-3","volume":"34","author":"C Gerrits","year":"1998","unstructured":"Gerrits C, Burris H, Schellens J, Planting A, van den Burg M, Rodriguez G et al (1998) Five days of oral topotecan (Hycamtin) a phase I and pharmacological study in adult patients with solid tumors. Eur J Cancer 34:1030\u20131035","journal-title":"Eur J Cancer"},{"key":"23_CR21","first-page":"69","volume":"5","author":"CJ Gerrits","year":"1999","unstructured":"Gerrits CJ, Schellens JH, Burris H, Eckhardt JR, Planting AS, van der Burg ME et al (1999) A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5:69\u201375","journal-title":"Clin Cancer Res"},{"key":"23_CR22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bjc.1996.243","volume":"73","author":"J Schellens","year":"1996","unstructured":"Schellens J, Creemers G, Beijen J, de Boer-Dennert M, McDonald M, Davies B, Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73:1268\u20131271","journal-title":"Br J Cancer"},{"key":"23_CR23","first-page":"868","volume":"6","author":"SC White","year":"2000","unstructured":"White SC, Cheesman S, Thatcher N, Anderson H, Carrington B, Hearn S et al (2000) Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 6:868\u2013873","journal-title":"Clin Cancer Res"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s002800000161","volume":"46","author":"A Montazeri","year":"2000","unstructured":"Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Deporte-Fety R et al (2000) Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 46:375\u2013381","journal-title":"Cancer Chemother Pharmacol"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.1996.14.12.3062","volume":"14","author":"S O\u2019Reilly","year":"1996","unstructured":"O\u2019Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS et al (1996) Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062\u20133073","journal-title":"J Clin Oncol"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.bjc.6601469","volume":"90","author":"F L\u00e9ger","year":"2004","unstructured":"L\u00e9ger F, Loos WJ, Fourcade J, Bugat R, Goffinet M, Mathijssen RHJ, Verweij J, Sparreboom A, Chatelut E (2004) Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 90:343\u2013347","journal-title":"Br J Cancer"},{"key":"23_CR27","first-page":"706","volume":"20","author":"LB Grochow","year":"1992","unstructured":"Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL et al (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706\u2013713","journal-title":"Drug Metab Dispos"},{"key":"23_CR28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00001813-200010000-00001","volume":"11","author":"WJ Loos","year":"2000","unstructured":"Loos WJ, Gelderblom HJ, Verweij J, Brouwer E, de Jonge MJ, Sparreboom A (2000) Gender-dependent pharmacokinetics of topotecan in adult patients. Anticancer Drugs 11:673\u2013680","journal-title":"Anticancer Drugs"},{"key":"23_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/bjc.1997.364","volume":"76","author":"E Jonsson","year":"1997","unstructured":"Jonsson E, Fridborg H, Csoka K, Dhar S, Sundstrom C, Nygren P, Larsson R (1997) Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76:211\u2013219","journal-title":"Br J Cancer"},{"key":"23_CR30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s002800050600","volume":"39","author":"CL Erickson-Miller","year":"1997","unstructured":"Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, Parchment RE (1997) Different toxicity of camptothecin, topotecan, and 9-aminocamptothecin to human, canine and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 39:467\u2013472","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-005-0023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0023-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T10:52:29Z","timestamp":1586429549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-005-0023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s00280-005-0023-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,13]]}}}